In Situ Sequencing: 10x Genomics, NanoString, and Vizgen $txg $brkr – Two Natural Capital
10x Genomics Xenium leads spatial genomics with superior FFPE tissue analysis, outperforming NanoString and Vizgen in transcript capture. Legal battles reshape in situ sequencing market, revealing critical platform performance differences.
Two Natural Capital's analysis reveals 10x Genomics' Xenium platform outperforms competitors in FFPE tissue studies, while legal battles reshape the in situ sequencing landscape.
Stock info:
- Ticker: TXG (NASDAQ)
- Position: Two Natural Capital does not explicitly disclose whether they hold positions in these stocks
Why it matters:
- 10x Genomics' Xenium platform demonstrates superior transcript capture and sensitivity in FFPE tissue samples compared to NanoString's CosMx (now Bruker) and Vizgen's MERSCOPE
- Platform selection depends on research needs: Xenium excels in transcript detection sensitivity, CosMx offers higher plexity (up to 6000 genes), while MERSCOPE performs better in cell segmentation for brain samples
- Ongoing patent litigation significantly impacts the competitive landscape, with NanoString's bankruptcy and acquisition by Bruker reshaping market dynamics
- Bruker faces financial challenges post-NanoString acquisition with declining operating income (from $437M to $253M) and cash reserves (from $488.3M to $183.4M)
- Advancements in NGS-based spatial technologies like 10x's Visium HD may cannibalize certain in situ sequencing applications, threatening companies without diversified portfolios
Zoom in:
- The critical trade-off in in situ platforms is between plexity (number of genes targeted) and sensitivity/specificity, with experts emphasizing that sensitivity remains paramount
- Bruker's NanoString business faces significant headwinds, including U.S. market restrictions on GeoMx products and challenges returning to pre-Chapter 11 revenue levels by 2025
- Legal disputes have reshaped competitive dynamics: 10x and Vizgen settled their litigation, while 10x's lawsuit against Bruker continues with a trial set for August 4th
- Platform performance varies by sample type: Xenium outperforms in FFPE tissues, while MERSCOPE excels in mouse brain studies
- Resolve Biosciences appears to be struggling with stability and communication issues, raising questions about its viability in the competitive landscape
FAQs:
What is in situ sequencing and why is it important?
In situ sequencing is a technology that allows researchers to visualize and quantify gene expression directly within tissue samples, providing subcellular resolution with spatial context. It's crucial for understanding complex cellular interactions in diseases like cancer, offering insights that traditional bulk or single-cell RNA sequencing cannot provide.
How does 10x Genomics' Xenium platform compare to competitors?
Xenium demonstrates superior transcript capture and sensitivity in FFPE tissue samples but has limitations in cell segmentation accuracy compared to Vizgen's MERSCOPE. It initially offered lower plexity than NanoString's CosMx but has been working to close this gap with higher-plex panels.
What are the key performance metrics for in situ sequencing platforms?
The three primary metrics are: transcript counts per gene (measuring sensitivity), plexity (number of genes that can be targeted simultaneously), and cell segmentation performance (accuracy in defining cellular boundaries).
How has litigation affected the in situ sequencing market?
Litigation has dramatically reshaped the competitive landscape. NanoString filed for Chapter 11 bankruptcy following legal battles with 10x Genomics and was subsequently acquired by Bruker. Ongoing lawsuits between 10x and Bruker, as well as previously settled disputes between 10x and Vizgen, continue to impact market dynamics and innovation.
What financial challenges is Bruker facing after acquiring NanoString's assets?
Bruker has experienced declining operating income (from $437M to $253M), a 50% stock price drop over the past year, and significantly reduced cash reserves (from $488.3M to $183.4M). The company faces challenges in returning NanoString's business to pre-Chapter 11 revenue levels by 2025.
Could NGS-based spatial technologies replace in situ sequencing?
While NGS-based spatial technologies like 10x's Visium HD are advancing to offer single-cell resolution and whole-transcriptome analysis, in situ methods maintain advantages for specific applications requiring subcellular resolution and targeted gene panels. However, companies without diversified portfolios may face increasing competitive pressure.
Which in situ platform is best for different research applications?
Platform selection should be based on specific research needs: Xenium excels in transcript detection sensitivity and FFPE tissue analysis, CosMx offers the highest plexity for broad gene panels, and MERSCOPE performs better in cell segmentation for brain samples.
Disclaimer
This summary is based on a report by Two Natural Capital. For the full, detailed analysis, please refer to the original source material: https://www.twonaturalcap.com/p/in-situ-sequencing-10x-genomics-nanostring
ShortReport.fyi is not the author or originator of the content provided in this publication. We act solely as a distributor of the content and do not endorse, verify, or take responsibility for the accuracy, completeness, or reliability of the information presented. Each author retains full ownership and responsibility for their respective content, including any opinions, projections, or analyses expressed therein.
This publication is for informational purposes only and should not be construed as legal, business, investment, or tax advice. Readers are advised to consult the original source material and seek guidance from qualified professionals before making any decisions based on the information contained herein.
ShortReport.fyi disclaims all liability for any loss or damage arising from reliance on the content provided by third parties. The views expressed in these materials are solely those of the respective authors and do not necessarily reflect the views or opinions of ShortReport.fyi.